INT105268

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.18
First Reported 2002
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 2
Total Number 2
Disease Relevance 0.22
Pain Relevance 0.05

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytoplasm (VEGFA, KDR) extracellular region (VEGFA, KDR) extracellular space (VEGFA)
growth (VEGFA) proteinaceous extracellular matrix (VEGFA) nucleus (KDR)
VEGFA (Homo sapiens)
KDR (Homo sapiens)
Pain Link Frequency Relevance Heat
headache 4 50.40 Quite High
Pain 1 40.40 Quite Low
Central nervous system 2 5.00 Very Low Very Low Very Low
Glutamate 2 5.00 Very Low Very Low Very Low
imagery 2 5.00 Very Low Very Low Very Low
withdrawal 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Cancer 2 61.84 Quite High
Sarcoma 1 56.64 Quite High
Toxicity 1 51.44 Quite High
Headache 3 50.40 Quite High
Apoptosis 9 50.00 Quite Low
Vomiting 4 47.84 Quite Low
Asthenia 1 41.20 Quite Low
Pain 1 40.40 Quite Low
Cv General 2 Under Development 1 38.24 Quite Low
Fever 1 35.68 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
SU5416 is a small molecule antiangiogenic agent that inhibits vascular endothelial growth factor (VEGF) stimulation of the KDR tyrosine kinase receptor.
VEGF Positive_regulation (stimulation) of KDR
1) Confidence 0.18 Published 2002 Journal Clin. Cancer Res. Section Abstract Doc Link 12231519 Disease Relevance 0.22 Pain Relevance 0.05
Upon activation of VEGFR2 by VEGF, VEGFR2 binds to dimeric PDCD10, translocates to the membrane, and becomes activated.
VEGF Positive_regulation (activation) of VEGFR2
2) Confidence 0.08 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2909203 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox